TY - JOUR AU - Romero, I. AU - Bast, R. C. PY - 2012 DA - 2012// TI - Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy JO - Endocrinology VL - 153 UR - https://doi.org/10.1210/en.2011-2123 DO - 10.1210/en.2011-2123 ID - Romero2012 ER - TY - JOUR AU - Vaughan, S. AU - Coward, J. I. AU - Bast, R. C. AU - Berchuck, A. AU - Berek, J. S. AU - Brenton, J. D. AU - Coukos, G. AU - Crum, C. C. AU - Drapkin, R. AU - Etemadmoghadam, D. AU - Friedlander, M. AU - Gabra, H. AU - Kaye, S. B. AU - Lord, C. J. AU - Lengyel, E. AU - Levine, D. A. AU - McNeish, I. A. AU - Menon, U. AU - Mills, G. B. AU - Nephew, K. P. AU - Oza, A. M. AU - Sood, A. K. AU - Stronach, E. A. AU - Walczak, H. AU - Bowtell, D. D. AU - Balkwill, F. R. PY - 2011 DA - 2011// TI - Rethinking ovarian cancer: recommendations for improving outcomes JO - Nat Rev Cancer VL - 11 UR - https://doi.org/10.1038/nrc3144 DO - 10.1038/nrc3144 ID - Vaughan2011 ER - TY - JOUR AU - Bast, R. C. AU - Hennessy, B. AU - Mills, G. B. PY - 2009 DA - 2009// TI - The biology of ovarian cancer: new opportunities for translation JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2644 DO - 10.1038/nrc2644 ID - Bast2009 ER - TY - JOUR AU - Kurman, R. J. AU - Shih Ie, M. PY - 2011 DA - 2011// TI - Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm JO - Hum Pathol VL - 42 UR - https://doi.org/10.1016/j.humpath.2011.03.003 DO - 10.1016/j.humpath.2011.03.003 ID - Kurman2011 ER - TY - JOUR AU - Coleman, R. L. AU - Monk, B. J. AU - Sood, A. K. AU - Herzog, T. J. PY - 2013 DA - 2013// TI - Latest research and treatment of advanced-stage epithelial ovarian cancer JO - Nat Rev Clin Oncol VL - 10 UR - https://doi.org/10.1038/nrclinonc.2013.5 DO - 10.1038/nrclinonc.2013.5 ID - Coleman2013 ER - TY - JOUR AU - Bast, R. C. PY - 2011 DA - 2011// TI - Molecular approaches to personalizing management of ovarian cancer JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdr516 DO - 10.1093/annonc/mdr516 ID - Bast2011 ER - TY - CHAP AU - Telleria, C. M. AU - Goyeneche, A. A. ED - Farghaly, S. PY - 2012 DA - 2012// TI - Antiprogestins in Ovarian Cancer BT - Ovarian Cancer -Clinical and Therapeutic Perspectives PB - InTechopen CY - Rijeka, Croatia ID - Telleria2012 ER - TY - JOUR AU - Goyeneche, A. A. AU - Caron, R. W. AU - Telleria, C. M. PY - 2007 DA - 2007// TI - Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-07-0164 DO - 10.1158/1078-0432.CCR-07-0164 ID - Goyeneche2007 ER - TY - JOUR AU - Freeburg, E. M. AU - Goyeneche, A. A. AU - Telleria, C. M. PY - 2009 DA - 2009// TI - Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment JO - Int J Oncol VL - 34 ID - Freeburg2009 ER - TY - JOUR AU - Gamarra-Luques, C. D. AU - Goyeneche, A. A. AU - Hapon, M. B. AU - Telleria, C. M. PY - 2012 DA - 2012// TI - Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-200 DO - 10.1186/1471-2407-12-200 ID - Gamarra-Luques2012 ER - TY - JOUR AU - Goyeneche, A. A. AU - Seidel, E. E. AU - Telleria, C. M. PY - 2012 DA - 2012// TI - Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2 JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9655-z DO - 10.1007/s10637-011-9655-z ID - Goyeneche2012 ER - TY - JOUR AU - Freeburg, E. M. AU - Goyeneche, A. A. AU - Seidel, E. E. AU - Telleria, C. M. PY - 2009 DA - 2009// TI - Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity JO - Cancer Cell Int VL - 9 UR - https://doi.org/10.1186/1475-2867-9-4 DO - 10.1186/1475-2867-9-4 ID - Freeburg2009 ER - TY - JOUR AU - Kurata, T. AU - Tamura, T. AU - Shinkai, T. AU - Ohe, Y. AU - Kunitoh, H. AU - Kodama, T. AU - Kakinuma, R. AU - Matsumoto, T. AU - Kubota, K. AU - Omatsu, H. AU - Nishiwaki, Y. AU - Saijo, N. PY - 2001 DA - 2001// TI - Phase I and pharmacological study of paclitaxel given over 3 h with cisplatin for advanced non-small cell lung cancer JO - Jpn J Clin Oncol VL - 31 UR - https://doi.org/10.1093/jjco/hye022 DO - 10.1093/jjco/hye022 ID - Kurata2001 ER - TY - JOUR AU - Himmelstein, K. J. AU - Patton, T. F. AU - Belt, R. J. AU - Taylor, S. AU - Repta, A. J. AU - Sternson, L. A. PY - 1981 DA - 1981// TI - Clinical kinetics on intact cisplatin and some related species JO - Clin Pharmacol Ther VL - 29 UR - https://doi.org/10.1038/clpt.1981.91 DO - 10.1038/clpt.1981.91 ID - Himmelstein1981 ER - TY - JOUR AU - du Bois, A. AU - Luck, H. J. AU - Buser, K. AU - Meerpohl, H. G. AU - Sessa, C. AU - Klaassen, U. AU - Meden, H. AU - Bochtler, H. AU - Diergarten, K. PY - 1997 DA - 1997// TI - Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum JO - Eur J Cancer VL - 33 UR - https://doi.org/10.1016/S0959-8049(97)89009-0 DO - 10.1016/S0959-8049(97)89009-0 ID - du Bois1997 ER - TY - JOUR AU - Langdon, S. P. AU - Lawrie, S. S. AU - Hay, F. G. AU - Hawkes, M. M. AU - McDonald, A. AU - Hayward, I. P. AU - Schol, D. J. AU - Hilgers, J. AU - Leonard, R. C. AU - Smyth, J. F. PY - 1988 DA - 1988// TI - Characterization and properties of nine human ovarian adenocarcinoma cell lines JO - Cancer Res VL - 48 ID - Langdon1988 ER - TY - JOUR AU - Cooke, S. L. AU - Ng, C. K. AU - Melnyk, N. AU - Garcia, M. J. AU - Hardcastle, T. AU - Temple, J. AU - Langdon, S. AU - Huntsman, D. AU - Brenton, J. D. PY - 2010 DA - 2010// TI - Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.245 DO - 10.1038/onc.2010.245 ID - Cooke2010 ER - TY - JOUR AU - Ormerod, M. G. AU - O'Neill, C. AU - Robertson, D. AU - Kelland, L. R. AU - Harrap, K. R. PY - 1996 DA - 1996// TI - cis- Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines JO - Cancer Chemother Pharmacol VL - 37 UR - https://doi.org/10.1007/s002800050413 DO - 10.1007/s002800050413 ID - Ormerod1996 ER - TY - JOUR AU - MdDermott, M. AU - Eustace, A. J. AU - Busschots, S. AU - Breen, L. AU - Crown, J. AU - Clynes, M. AU - O'Donovan, N. AU - Stordal, B. PY - 2014 DA - 2014// TI - In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies JO - Frontiers Oncol VL - 4 ID - MdDermott2014 ER - TY - JOUR AU - Katano, K. AU - Kondo, A. AU - Safaei, R. AU - Holzer, A. AU - Samimi, G. AU - Mishima, M. AU - Kuo, Y. M. AU - Rochdi, M. AU - Howell, S. B. PY - 2002 DA - 2002// TI - Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper JO - Cancer Res VL - 62 ID - Katano2002 ER - TY - JOUR AU - Ledermann, J. A. AU - Kristeleit, R. S. PY - 2010 DA - 2010// TI - Optimal treatment for relapsing ovarian cancer JO - Ann Oncol VL - 21 ID - Ledermann2010 ER - TY - JOUR AU - Stordal, B. AU - Hamon, M. AU - McEneaney, V. AU - Roche, S. AU - Gillet, J. P. AU - O'Leary, J. J. AU - Gottesman, M. AU - Clynes, M. PY - 2012 DA - 2012// TI - Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0040717 DO - 10.1371/journal.pone.0040717 ID - Stordal2012 ER - TY - JOUR AU - Yan, X. D. AU - Li, M. AU - Yuan, Y. AU - Mao, N. AU - Pan, L. Y. PY - 2007 DA - 2007// TI - Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations JO - Oncol Rep VL - 17 ID - Yan2007 ER - TY - JOUR AU - Lu, X. AU - Errington, J. AU - Curtin, N. J. AU - Lunec, J. AU - Newell, D. R. PY - 2001 DA - 2001// TI - The impact of p53 status on cellular sensitivity to antifolate drugs JO - Clin Cancer Res VL - 7 ID - Lu2001 ER - TY - JOUR AU - Siddik, Z. H. AU - Mims, B. AU - Lozano, G. AU - Thai, G. PY - 1998 DA - 1998// TI - Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line JO - Cancer Res VL - 58 ID - Siddik1998 ER - TY - JOUR AU - Debernardis, D. AU - Sire, E. G. AU - De Feudis, P. AU - Vikhanskaya, F. AU - Valenti, M. AU - Russo, P. AU - Parodi, S. AU - D'Incalci, M. AU - Broggini, M. PY - 1997 DA - 1997// TI - p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel JO - Cancer Res VL - 57 ID - Debernardis1997 ER - TY - JOUR AU - Righetti, S. C. AU - Perego, P. AU - Corna, E. AU - Pierotti, M. A. AU - Zunino, F. PY - 1999 DA - 1999// TI - Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection JO - Cell Growth Differ VL - 10 ID - Righetti1999 ER - TY - JOUR AU - Yaginuma, Y. AU - Westphal, H. PY - 1992 DA - 1992// TI - Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines JO - Cancer Res VL - 52 ID - Yaginuma1992 ER - TY - JOUR AU - O'Connor, P. M. AU - Jackman, J. AU - Bae, I. AU - Myers, T. G. AU - Fan, S. AU - Mutoh, M. AU - Scudiero, D. A. AU - Monks, A. AU - Sausville, E. A. AU - Weinstein, J. N. AU - Friend, S. AU - Fornace, A. J. AU - Kohn, K. W. PY - 1997 DA - 1997// TI - Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents JO - Cancer Res VL - 57 ID - O'Connor1997 ER - TY - JOUR AU - Berglind, H. AU - Pawitan, Y. AU - Kato, S. AU - Ishioka, C. AU - Soussi, T. PY - 2008 DA - 2008// TI - Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination JO - Cancer Biol Ther VL - 7 UR - https://doi.org/10.4161/cbt.7.5.5712 DO - 10.4161/cbt.7.5.5712 ID - Berglind2008 ER - TY - JOUR AU - Hamroun, D. AU - Kato, S. AU - Ishioka, C. AU - Claustres, M. AU - Beroud, C. AU - Soussi, T. PY - 2006 DA - 2006// TI - The UMD TP53 database and website: update and revisions JO - Hum Mutat VL - 27 UR - https://doi.org/10.1002/humu.20269 DO - 10.1002/humu.20269 ID - Hamroun2006 ER - TY - JOUR AU - Belanger, A. AU - Philibert, D. AU - Teutsch, G. PY - 1981 DA - 1981// TI - Regio and stereospecific synthesis of 11 beta- substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity - (1) JO - Steroids VL - 37 UR - https://doi.org/10.1016/0039-128X(81)90039-8 DO - 10.1016/0039-128X(81)90039-8 ID - Belanger1981 ER - TY - JOUR AU - Benagiano, G. AU - Bastianelli, C. AU - Farris, M. PY - 2008 DA - 2008// TI - Selective progesterone receptor modulators 1: use during pregnancy JO - Expert Opin Pharmacother VL - 9 UR - https://doi.org/10.1517/14656566.9.14.2459 DO - 10.1517/14656566.9.14.2459 ID - Benagiano2008 ER - TY - JOUR AU - Moller, C. AU - Hoffmann, J. AU - Kirkland, T. A. AU - Schwede, W. PY - 2008 DA - 2008// TI - Investigational developments for the treatment of progesterone-dependent diseases JO - Expert Opin Investig Drugs VL - 17 UR - https://doi.org/10.1517/13543784.17.4.469 DO - 10.1517/13543784.17.4.469 ID - Moller2008 ER - TY - JOUR AU - Attardi, B. J. AU - Burgenson, J. AU - Hild, S. A. AU - Reel, J. R. AU - Blye, R. P. PY - 2002 DA - 2002// TI - CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914 JO - Mol Cell Endocrinol VL - 188 UR - https://doi.org/10.1016/S0303-7207(01)00743-2 DO - 10.1016/S0303-7207(01)00743-2 ID - Attardi2002 ER - TY - JOUR AU - Leonhardt, S. A. AU - Edwards, D. P. PY - 2002 DA - 2002// TI - Mechanism of action of progesterone antagonists JO - Exp Biol Med (Maywood) VL - 227 ID - Leonhardt2002 ER - TY - JOUR AU - Telleria, C. M. PY - 2012 DA - 2012// TI - Drug Repurposing for Cancer Therapy JO - J Cancer Sci Ther VL - 4 UR - https://doi.org/10.4172/1948-5956.1000e108 DO - 10.4172/1948-5956.1000e108 ID - Telleria2012 ER - TY - JOUR AU - Spitz, I. M. PY - 2009 DA - 2009// TI - Clinical utility of progesterone receptor modulators and their effect on the endometrium JO - Curr Opin Obstet Gynecol VL - 21 UR - https://doi.org/10.1097/GCO.0b013e32832e07e8 DO - 10.1097/GCO.0b013e32832e07e8 ID - Spitz2009 ER - TY - JOUR AU - Attardi, B. J. AU - Burgenson, J. AU - Hild, S. A. AU - Reel, J. R. PY - 2004 DA - 2004// TI - In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone JO - J Steroid Biochem Mol Biol VL - 88 UR - https://doi.org/10.1016/j.jsbmb.2003.12.004 DO - 10.1016/j.jsbmb.2003.12.004 ID - Attardi2004 ER - TY - JOUR AU - Tieszen, C. R. AU - Goyeneche, A. A. AU - Brandhagen, B. N. AU - Ortbahn, C. T. AU - Telleria, C. M. PY - 2011 DA - 2011// TI - Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non- reproductive origin regardless of progesterone receptor expression JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-207 DO - 10.1186/1471-2407-11-207 ID - Tieszen2011 ER - TY - JOUR AU - Liang, Y. AU - Hou, M. AU - Kallab, A. M. AU - Barrett, J. T. AU - El Etreby, F. AU - Schoenlein, P. V. PY - 2003 DA - 2003// TI - Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1 JO - Int J Oncol VL - 23 ID - Liang2003 ER - TY - JOUR AU - Kadmiel, M. AU - Cidlowski, J. A. PY - 2013 DA - 2013// TI - Glucocorticoid receptor signaling in health and disease JO - Trends Pharmacol Sci VL - 34 UR - https://doi.org/10.1016/j.tips.2013.07.003 DO - 10.1016/j.tips.2013.07.003 ID - Kadmiel2013 ER - TY - JOUR AU - Lewis-Tuffin, L. J. AU - Jewell, C. M. AU - Bienstock, R. J. AU - Collins, J. B. AU - Cidlowski, J. A. PY - 2007 DA - 2007// TI - Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active JO - Mol Cell Biol VL - 27 UR - https://doi.org/10.1128/MCB.01439-06 DO - 10.1128/MCB.01439-06 ID - Lewis-Tuffin2007 ER -